- FDA says data present "a consistent and favorable safety profile for ATX-101."
- FDA advisory panel to meet the morning of March 9 to discuss Kythera's (NASDAQ:KYTH) application seeking approval for ATX-101 to treat double chin. It would be the first drug to treat double chin.
- Annual sales of ATX-101 may reach $510M by 2020.
- Shares +4.2% premarket.
- Link: FDA brief